OliX Pharmaceuticals,Inc
226950.KQFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
4
Cost of Revenue
2
Gross Profit
2
Gross Margin
53.7%
Operating Income
-23
Operating Margin
-544.6%
Net Income
-30
Net Margin
-716.2%
EPS (Basic)
$-2.00
EPS (Diluted)
$-2.00
EBITDA
-21
EBITDA Margin
-498.4%
2023
12/31/2023
Revenue
13
Cost of Revenue
2
Gross Profit
11
Gross Margin
84.5%
Operating Income
-14
Operating Margin
-106.6%
Net Income
-14
Net Margin
-111.9%
EPS (Basic)
$-1.00
EPS (Diluted)
$-1.00
EBITDA
-12
EBITDA Margin
-91.1%
2022
12/31/2022
Revenue
7
Cost of Revenue
1
Gross Profit
6
Gross Margin
78.8%
Operating Income
-17
Operating Margin
-240.1%
Net Income
-15
Net Margin
-209.2%
EPS (Basic)
$-1.00
EPS (Diluted)
$-1.00
EBITDA
-18
EBITDA Margin
-259.7%
2021
12/31/2021
Revenue
3
Cost of Revenue
6
Gross Profit
-4
Gross Margin
-127.4%
Operating Income
-18
Operating Margin
-659.4%
Net Income
-22
Net Margin
-808.7%
EPS (Basic)
$-2.00
EPS (Diluted)
$-2.00
EBITDA
-19
EBITDA Margin
-706.3%
2020
12/31/2020
Revenue
2
Cost of Revenue
1
Gross Profit
1
Gross Margin
44.0%
Operating Income
-12
Operating Margin
-656.4%
Net Income
-15
Net Margin
-783.4%
EPS (Basic)
$-1.00
EPS (Diluted)
$-1.00
EBITDA
-14
EBITDA Margin
-771.1%